Europe Nuclear Medicine Market worth $5.15 billion by 2030
The report "Europe Nuclear Medicine Market by Type (SPECT [Tc99m, I-123], PET [F-18, Rb-82], Alpha Emitters, Beta Emitters [Y-90, I-131], Brachytherapy), Application (Onco, Cardio), Procedure, End User (Imaging Center, Hospital), Market Growth - Forecast to 2030" is projected to grow from USD 2.47 billion in 2025 and to reach USD 5.15 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 15.8% during the forecast period.
Browse 170 market data Tables and 10 Figures spread through 250 Pages and in-depth TOC on "Europe Nuclear Medicine Market by Type (SPECT [Tc99m, I-123], PET [F-18, Rb-82], Alpha Emitters, Beta Emitters [Y-90, I-131], Brachytherapy), Application (Onco, Cardio), Procedure, End User (Imaging Center, Hospital), Market Growth - Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-nuclear-medicine-market-133112683.html
This expansion is due to the rising demand for radiopharmaceuticals and radioisotopes in diagnostic and targeted delivery of radionuclide therapies, especially the use of radiopharmaceuticals in oncology. The growth of the market is being fueled by the increasing prevalence of cancer, an ageing population, and high adoption of PET and SPECT procedures in the key European nations. Additionally, theranostics, improved access to therapeutic radioisotopes, including lutetium-177, and favorable regulatory and research efforts throughout Europe are also contributing to the increase in the nuclear medicine market.
“The diagnostic nuclear medicine segment accounted for the largest share of the Europe nuclear medicine market, by type.”
In 2024, the diagnostic nuclear medicine segment accounted for the largest share of the Europe nuclear medicine market. This is due to the large number of PET and SPECT imaging procedures performed in the region. This segment dominance is supported by strong clinical dependence on diagnostic radiopharmaceuticals for early detection, staging, and monitoring diseases, especially cancer, cardiovascular, and neurological diseases. The easy access to well-established radioisotopes (technetium-99m and fluorine-18), and the strength of the imaging infrastructure and excellent reimbursement for diagnostic scans in Europe further support the dominant status of diagnostic nuclear medicine in the local market.
“The hospitals segment is the fastest-growing segment during the forecast period, by end user.”
In 2024, the hospitals segment is expected to register the fastest growth rate during the forecast period. The increasing integration of nuclear medicine services in hospitals facilitates the provision of comprehensive diagnosis & treatment services under one roof, thus increasing its growth. The increased use of advanced PET/CT and SPECT/CT systems, which live up to in-house radiopharmacy, and the increased use of therapeutic radiopharmaceuticals in the treatment of cancer, are driving demand at hospitals. Moreover, increased patient flow, accessibility to specialized clinical skills, and better reimbursement of nuclear medicine interventions in the European healthcare systems are sustaining the growth of the hospital segment.
Germany has the greatest market share of the Europe nuclear medicine market. This growth is due to the advanced healthcare infrastructure in the country, high adoption of PET and SPECT imaging systems, and good accessibility to radiopharmaceuticals and radioisotopes, both in diagnostic and therapeutic applications. High volumes of procedures in Germany are promoted by its leadership in nuclear medicine research, early adoption of theranostics, and the availability of proven radiopharmaceutical manufacturers and radiopharmacies. Additionally, the good reimbursement policy, the proximity of nuclear medicine centers, and effective collaboration of hospitals, research institutes, and players in the industry support the leadership position of Germany in the European nuclear medicine market.
Key Players
The key players functioning in the Europe nuclear medicine market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.P.A (Italy), Pharmalogic Holdings Corp. (US), Sun Pharmaceutical Industries, Inc. (India), Nordion Inc. (Canada), Siemens Healthineers AG (Germany), NorthStar Medical Radiosiotopes, LLC (US), Eckert & Ziegler (Germany), Medi-Radiopharma (Hungary), SHINE Technologies, LLC (US), Telix Pharmaceuticals Limited (Australia), PDRadiopharma Inc. (Japan), ITM Isotope Technologies Munich SE (Germany), BWX Technologies Inc. (US), Isotopia (Israel), Institutes of Isotopes (Hungary), IRE Elit (Turkey), Cyclopharm (Australia), and RadioMedix, Inc. (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Europe Nuclear Medicine Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
